Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.56 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | MAX | P61244 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948321 | 0.74 | STS (0.57) | STSMYCMAXCHRM2CHRM1 | |
| SCHEMBL2923959 | 0.72 | STS (1.00) | STSMYCMAX | |
| SCHEMBL2922133 | 0.71 | CHRM2 (0.48) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL15437709 | 0.71 | CHRM2 (0.48) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2924960 | 0.71 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL8011456 | 0.68 | STS (0.70) | STSMYCMAX | |
| SCHEMBL22801858 | 0.68 | CHRM2 (0.54) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2919064 | 0.66 | STS (0.66) | STSMYCMAX | |
| SCHEMBL2919071 | 0.66 | STS (0.66) | STSMYCMAX | |
| SCHEMBL15437439 | 0.63 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1861098-A1 | ANTI-INFLAMMATORY COMPOUNDS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861099-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097292-A1 | ANTI-INFLAMMATORY COMPOUNDS | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| EP-1436253-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003031397-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | STS 1/4885MYC 2565/4885MAX 3361/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | STS 1/4885MYC 4795/4885MAX 4794/4885 |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | STS 1/4885MYC 4823/4885MAX 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.